BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30799513)

  • 1. Filamin A and DRD2 expression in corticotrophinomas.
    Sickler T; Trarbach EB; Frassetto FP; Dettoni JB; Alves VAF; Fragoso MCBV; Machado MC; Cardoso EF; Bronstein MD; Glezer A
    Pituitary; 2019 Apr; 22(2):163-169. PubMed ID: 30799513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
    Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
    Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
    Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
    J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
    Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G
    Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.
    Zhang S; Zhong M; Zhu H; You Q; Yuan H; Li Y
    Cancer Genet; 2023 Nov; 278-279():71-78. PubMed ID: 37729778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
    Bueno C; Trarbach EB; Bronstein MD; Glezer A
    Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors].
    Liu YT; Zhang Y; Wang Y; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1703-1706. PubMed ID: 31216815
    [No Abstract]   [Full Text] [Related]  

  • 11. Interactions between filamin A and MMP-9 regulate proliferation and invasion in renal cell carcinoma.
    Sun GG; Wei CD; Jing SW; Hu WN
    Asian Pac J Cancer Prev; 2014; 15(8):3789-95. PubMed ID: 24870795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
    Sato A; Hara Y
    Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filamin A is reduced and contributes to the CASR sensitivity in human parathyroid tumors.
    Mingione A; Verdelli C; Ferrero S; Vaira V; Guarnieri V; Scillitani A; Vicentini L; Balza G; Beretta E; Terranegra A; Vezzoli G; Soldati L; Corbetta S
    J Mol Endocrinol; 2017 Feb; 58(2):91-103. PubMed ID: 27872158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
    Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy.
    Donadon M; Di Tommaso L; Soldani C; Franceschini B; Terrone A; Mimmo A; Vitali E; Roncalli M; Lania A; Torzilli G
    Liver Int; 2018 Feb; 38(2):303-311. PubMed ID: 28727243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filamin A and parafibromin expression in parathyroid carcinoma.
    Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
    Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours.
    Toledo J; Perez PA; Zanetti M; Díaz-Torga G; Mukdsi JH; Gutierrez S
    J Endocrinol; 2024 Jan; 260(1):. PubMed ID: 37855268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas.
    Pawlikowski M
    Folia Histochem Cytobiol; 2010 Sep; 48(3):394-7. PubMed ID: 21071344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cancer suppressor gene for colorectal adenocarcinoma: filamin A.
    Tian ZQ; Shi JW; Wang XR; Li Z; Wang GY
    World J Gastroenterol; 2015 Feb; 21(7):2199-205. PubMed ID: 25717257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours.
    Wang FF; Tang KT; Yen YS; Ho DM; Yang AH; Huang CI; Lin HD; Won JG
    Clin Endocrinol (Oxf); 2012 Feb; 76(2):253-63. PubMed ID: 21781143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.